Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × reparixin × Breast × Clear all
NCT02370238 2022-09-16

FRIDA

Dompé Farmaceutici S.p.A

Phase 2 Completed
194 enrolled 19 charts
Breast

Breast Neoplasms

NCT01861054 2021-05-14

Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer

Dompé Farmaceutici S.p.A

Phase 2 Terminated
20 enrolled 16 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡